Nathan Hannah L, de Greeff Annemarie, Hezelgrave Natasha L, Chappell Lucy C, Shennan Andrew H
Women's Health Academic Centre, King's College London, London, UK.
Blood Press Monit. 2015 Feb;20(1):52-5. doi: 10.1097/MBP.0000000000000086.
To assess the accuracy of the Microlife 3AS1-2 blood pressure device in pregnancy and pre-eclampsia in a low-resource setting.
Prospective validation according to the British Hypertension Society protocol. A total of 45 pregnant women were recruited from Kimberley Hospital (South Africa), of whom 15 had pre-eclampsia.
The Microlife 3AS1-2 device achieved an overall B/A grade in pregnancy (including pre-eclampsia), passing the British Hypertension Society protocol requirements and achieving the International Organization for Standardization standard with a mean difference and SD of -3.8 ± 7.3 and -1.5 ± 6.2 mmHg for systolic and diastolic pressures, respectively.
The Microlife 3AS1-2 device can be recommended for use in pregnancy, including pre-eclampsia. In addition, it fulfils the requirements stipulated by the WHO for an automated blood pressure device suitable for use in a low-resource setting. This makes it the ideal device for antenatal clinics and primary healthcare facilities in low-income and middle-income countries.
在资源匮乏地区评估迈克大夫3AS1-2血压测量仪在孕期及子痫前期的准确性。
按照英国高血压学会方案进行前瞻性验证。从南非金伯利医院招募了45名孕妇,其中15名患有子痫前期。
迈克大夫3AS1-2血压测量仪在孕期(包括子痫前期)总体达到B/A级,通过了英国高血压学会方案要求,并达到了国际标准化组织标准,收缩压和舒张压的平均差值及标准差分别为-3.8±7.3 mmHg和-1.5±6.2 mmHg。
迈克大夫3AS1-2血压测量仪可推荐用于孕期,包括子痫前期。此外,它符合世界卫生组织对适用于资源匮乏地区的自动血压测量仪的规定要求。这使其成为低收入和中等收入国家产前诊所及初级医疗保健机构的理想设备。